HSITF (Hadasit Bio Holdings) Return-on-Tangible-Equity: -461.95% (As of Dec. 2025)


HSITF Hadasit Bio Holdings Ltd HSITF
14 GF Score
Price $0.12
! 3 Warning Signs
View Full Analysis

What is Hadasit Bio Holdings Return-on-Tangible-Equity?

Hadasit Bio Holdings HSITF 14 Return-on-Tangible-Equity is -461.95% as of Dec. 2025. GuruFocus rates HSITF with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 1,206 Biotechnology companies, Hadasit Bio Holdings ranks worse than 87.73% on this metric.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Hadasit Bio Holdings's annualized net income for the quarter that ended in Dec. 2025 was $-0.52 Mil. Hadasit Bio Holdings's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $0.11 Mil. Therefore, Hadasit Bio Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -461.95%.

The historical rank and industry rank for Hadasit Bio Holdings's Return-on-Tangible-Equity or its related term are showing as below:

HSITF' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -223.62   Med: -39.91   Max: 146.99
Current: -223.62

During the past 13 years, Hadasit Bio Holdings's highest Return-on-Tangible-Equity was 146.99%. The lowest was -223.62%. And the median was -39.91%.

HSITF's Return-on-Tangible-Equity is ranked worse than
87.73% of 1206 companies
in the Biotechnology industry
Industry Median: -42.53 vs HSITF: -223.62

Hadasit Bio Holdings  (OTCPK:HSITF) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Hadasit Bio Holdings Return-on-Tangible-Equity Related Terms


Hadasit Bio Holdings Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for Hadasit Bio Holdings's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hadasit Bio Holdings Return-on-Tangible-Equity Chart

Hadasit Bio Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 55.22 -61.00 -143.60 -103.55 -213.36

Hadasit Bio Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -125.68 -115.27 -107.77 -161.13 -461.95

HSITF vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison

For the Biotechnology subindustry, Hadasit Bio Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hadasit Bio Holdings Return-on-Tangible-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hadasit Bio Holdings's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Hadasit Bio Holdings's Return-on-Tangible-Equity falls into.


HSITF
14GF Score
Hadasit Bio Holdings Ltd HSITF
Return-on-Tangible-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hadasit Bio Holdings Return-on-Tangible-Equity Calculation

Hadasit Bio Holdings's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-0.575/( (0.545+-0.006 )/ 2 )
=-0.575/0.2695
=-213.36 %

Hadasit Bio Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-0.522/( (0.232+-0.006)/ 2 )
=-0.522/0.113
=-461.95 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2025) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of -461.95% mean?
Hadasit Bio Holdings (HSITF) has a Return-on-Tangible-Equity of -461.95% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Hadasit Bio Holdings and its competitors. According to the industry distribution chart, Hadasit Bio Holdings ranks #1058 out of 1206 companies in the Biotechnology industry, placing it in the top 87.7%.
Is Hadasit Bio Holdings' Return-on-Tangible-Equity too high?
Hadasit Bio Holdings' current Return-on-Tangible-Equity is -461.95%. Based on the distribution chart, Hadasit Bio Holdings ranks #1058 out of 1206 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Hadasit Bio Holdings has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Hadasit Bio Holdings' Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hadasit Bio Holdings ranks #1058 out of 1206 companies for Return-on-Tangible-Equity. This places Hadasit Bio Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Hadasit Bio Holdings and its competitors. Hadasit Bio Holdings's current Return-on-Tangible-Equity is -461.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hadasit Bio Holdings stock overvalued right now?
Hadasit Bio Holdings (HSITF) has a current Return-on-Tangible-Equity of -461.95%. The current Return-on-Tangible-Equity is -461.95%. Hadasit Bio Holdings' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Hadasit Bio Holdings (HSITF), the current Return-on-Tangible-Equity is -461.95% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hadasit Bio Holdings Business Description

Other Exchanges HDST-M:Israel
Address 5th Floor, Jerusaelm Bio-Park, Hadassah Ein-Kerem Campus, Jerusalem, ISR, 91120
Hadasit Bio Holdings Ltd serves as a precedent in the field of biotech financing. It is engaged in the advancement and enhancement of its portfolio companies. Its portfolio companies are involved in the field of medical and biotechnological research and production and distribution of the results of the research and development done in these areas.
14GF Score

Get the complete analysis for HSITF

Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.12
Price